-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network, May 27 News On May 25, CSPC issued an announcement stating that the new class 1 drug SYHX1903 was approved for clinical trials in China.
SYHX1903 is a highly selective CDK9 inhibitor, indicated for hematological malignancies.
Since the beginning of this year, CSPC has already obtained 8 Class 1 new drugs approved for clinical use in China.
SYHX1903 is a highly selective CDK9 inhibitor, indicated for hematological malignancies.
Since the beginning of this year, CSPC has already obtained 8 Class 1 new drugs approved for clinical use in China.
SYHX1903 is a highly selective cyclin-dependent protein kinase 9 (CDK9) inhibitor, which has great potential in the treatment of malignant hematoma and solid tumors that target CDK9.
The indication for this approved clinical trial is malignant hematological tumors .
In the later stage, CSPC plans to apply for clinical trials for advanced solid tumor indications.
The indication for this approved clinical trial is malignant hematological tumors .
In the later stage, CSPC plans to apply for clinical trials for advanced solid tumor indications.
As a traditional pharmaceutical company that has successfully completed innovation and transformation in China, CSPC adheres to an innovative R&D strategy.
In the past three years, CSPC has continued to increase investment in research and development, and the compound growth rate of research and development expenses has reached 46.
7%.
In 2020, CSPC's research and development expenses increased significantly to 2.
89 billion yuan, a year-on-year increase of 44.
5%.
In the past three years, CSPC has continued to increase investment in research and development, and the compound growth rate of research and development expenses has reached 46.
7%.
In 2020, CSPC's research and development expenses increased significantly to 2.
89 billion yuan, a year-on-year increase of 44.
5%.
2018-2020 R&D expenses of CSPC (unit: 100 million yuan)
With substantial investment in research and development, CSPC is steadily advancing its innovative research and development.
Since 2021, CSPC Group has a total of 8 Class 1 new drugs approved for clinical trials in China, including SYHX1903, SYHX1901, SKLB1028, SYHA1811, JMT601, NBL-012, recombinant anti-PD-1 fully human monoclonal antibody, recombinant humanized Anti-epidermal growth factor receptor monoclonal antibodies, etc.
In addition, 3 new drugs have been approved for clinical use in the United States, including NBL-015, JMT601 and NBL-012.
Since 2021, CSPC Group has a total of 8 Class 1 new drugs approved for clinical trials in China, including SYHX1903, SYHX1901, SKLB1028, SYHA1811, JMT601, NBL-012, recombinant anti-PD-1 fully human monoclonal antibody, recombinant humanized Anti-epidermal growth factor receptor monoclonal antibodies, etc.
In addition, 3 new drugs have been approved for clinical use in the United States, including NBL-015, JMT601 and NBL-012.
Since 2021, CSPC has been approved as a domestic clinical Class 1 new drug
Data source: Mi Nei.
com database, company announcement
com database, company announcement
Medical Network, May 27 News On May 25, CSPC issued an announcement stating that the new class 1 drug SYHX1903 was approved for clinical trials in China.
SYHX1903 is a highly selective CDK9 inhibitor, indicated for hematological malignancies.
Since the beginning of this year, CSPC has already obtained 8 Class 1 new drugs approved for clinical use in China.
SYHX1903 is a highly selective CDK9 inhibitor, indicated for hematological malignancies.
Since the beginning of this year, CSPC has already obtained 8 Class 1 new drugs approved for clinical use in China.
SYHX1903 is a highly selective cyclin-dependent protein kinase 9 (CDK9) inhibitor, which has great potential in the treatment of malignant hematoma and solid tumors that target CDK9.
The indication for this approved clinical trial is malignant hematological tumors .
In the later stage, CSPC plans to apply for clinical trials for advanced solid tumor indications.
The indication for this approved clinical trial is malignant hematological tumors .
In the later stage, CSPC plans to apply for clinical trials for advanced solid tumor indications.
As a traditional pharmaceutical company that has successfully completed innovation and transformation in China, CSPC adheres to an innovative R&D strategy.
In the past three years, CSPC has continued to increase investment in research and development, and the compound growth rate of research and development expenses has reached 46.
7%.
In 2020, CSPC's research and development expenses increased significantly to 2.
89 billion yuan, a year-on-year increase of 44.
5%.
In the past three years, CSPC has continued to increase investment in research and development, and the compound growth rate of research and development expenses has reached 46.
7%.
In 2020, CSPC's research and development expenses increased significantly to 2.
89 billion yuan, a year-on-year increase of 44.
5%.
2018-2020 R&D expenses of CSPC (unit: 100 million yuan)
With substantial investment in research and development, CSPC is steadily advancing its innovative research and development.
Since 2021, CSPC Group has a total of 8 Class 1 new drugs approved for clinical trials in China, including SYHX1903, SYHX1901, SKLB1028, SYHA1811, JMT601, NBL-012, recombinant anti-PD-1 fully human monoclonal antibody, recombinant humanized Anti-epidermal growth factor receptor monoclonal antibodies, etc.
In addition, 3 new drugs have been approved for clinical use in the United States, including NBL-015, JMT601 and NBL-012.
Since 2021, CSPC Group has a total of 8 Class 1 new drugs approved for clinical trials in China, including SYHX1903, SYHX1901, SKLB1028, SYHA1811, JMT601, NBL-012, recombinant anti-PD-1 fully human monoclonal antibody, recombinant humanized Anti-epidermal growth factor receptor monoclonal antibodies, etc.
In addition, 3 new drugs have been approved for clinical use in the United States, including NBL-015, JMT601 and NBL-012.
Since 2021, CSPC has been approved as a domestic clinical Class 1 new drug
Data source: Mi Nei.
com database, company announcement
com database, company announcement
Medical Network, May 27 News On May 25, CSPC issued an announcement stating that the new class 1 drug SYHX1903 was approved for clinical trials in China.
SYHX1903 is a highly selective CDK9 inhibitor, indicated for hematological malignancies.
Since the beginning of this year, CSPC has already obtained 8 Class 1 new drugs approved for clinical use in China.
SYHX1903 is a highly selective CDK9 inhibitor, indicated for hematological malignancies.
Since the beginning of this year, CSPC has already obtained 8 Class 1 new drugs approved for clinical use in China.
SYHX1903 is a highly selective cyclin-dependent protein kinase 9 (CDK9) inhibitor, which has great potential in the treatment of malignant hematoma and solid tumors that target CDK9.
The indication for this approved clinical trial is malignant hematological tumors .
In the later stage, CSPC plans to apply for clinical trials for advanced solid tumor indications.
Tumor tumor tumorThe indication for this approved clinical trial is malignant hematological tumors .
In the later stage, CSPC plans to apply for clinical trials for advanced solid tumor indications.
As a traditional pharmaceutical company that has successfully completed innovation and transformation in China, CSPC adheres to an innovative R&D strategy.
In the past three years, CSPC has continued to increase investment in research and development, and the compound growth rate of research and development expenses has reached 46.
7%.
In 2020, CSPC's research and development expenses increased significantly to 2.
89 billion yuan, a year-on-year increase of 44.
5%.
In the past three years, CSPC has continued to increase investment in research and development, and the compound growth rate of research and development expenses has reached 46.
7%.
In 2020, CSPC's research and development expenses increased significantly to 2.
89 billion yuan, a year-on-year increase of 44.
5%.
2018-2020 R&D expenses of CSPC (unit: 100 million yuan)
With substantial investment in research and development, CSPC is steadily advancing its innovative research and development.
Since 2021, CSPC Group has a total of 8 Class 1 new drugs approved for clinical trials in China, including SYHX1903, SYHX1901, SKLB1028, SYHA1811, JMT601, NBL-012, recombinant anti-PD-1 fully human monoclonal antibody, recombinant humanized Anti-epidermal growth factor receptor monoclonal antibodies, etc.
In addition, 3 new drugs have been approved for clinical use in the United States, including NBL-015, JMT601 and NBL-012.
Since 2021, CSPC Group has a total of 8 Class 1 new drugs approved for clinical trials in China, including SYHX1903, SYHX1901, SKLB1028, SYHA1811, JMT601, NBL-012, recombinant anti-PD-1 fully human monoclonal antibody, recombinant humanized Anti-epidermal growth factor receptor monoclonal antibodies, etc.
In addition, 3 new drugs have been approved for clinical use in the United States, including NBL-015, JMT601 and NBL-012.
Since 2021, CSPC has been approved as a domestic clinical Class 1 new drug
Data source: Mi Nei.
com database, company announcement
com database, company announcement
